Phase 3 RCT in 689 patients with proliferative diabetic retinopathy: brolucizumab 6 mg was noninferior and superior to panretinal laser for vision at week 54 (+0.2 vs −4.2 letters). Intraocular inflammation was higher with brolucizumab (5.2% vs 0.6%).
RCTn = 689
Wolf et al. Brolucizumab in the Treatment of Proliferative Diabetic Retinopathy: The CONDOR Randomized Clinical Trial